VEGF-A Polyclonal Antibody | ABP56497

VEGF-A Polyclonal Antibody | ABP56497 | Gentaur UK, US & Europe Distribution

Immunogen: Synthesized peptide derived from the Internal region of human VEGF-A

Product Category: Protein

Application: Protein General Reagents

Product Type: Primary Antibody

Host: Rabbit

Reactivity: Human, Mouse, Rat

Application: IHC-P, IF, ELISA

Application Note: Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: IHC-P (1:100-1:300), ELISA (1:10000) . Not yet tested in other applications.

Clonality: Polyclonal

Isotype: Rabbit IgG

Formulation: Liquid solution

Kit Component: N/A

Concentration: 1 mg/ml

Storage Buffer: PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide.

Storage Instructions: Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.

Shipping Condition: Gel pack with blue ice.

Background: VEGFA (vascular endothelial growth factor A) is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of VEGFA in mice resulted in abnormal embryonic blood vessel formation. VEGFA is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of VEGFA have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site.

Alternative Names: VEGFA; VEGF; Vascular endothelial growth factor A; VEGF-A; Vascular permeability factor; VPF

Precaution: The product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.